Recent Updates
Recently added Catalysts
BHST Positive Sentiment Score: 70/100

BioHarvest Sciences Amended Insider Trading Policy

Key Takeaway: BioHarvest Sciences Inc. has announced an amended insider trading policy, aimed at establishing a more reasonable trading window for its shareholders. The new trading window will open after two full trading days following the public release of quarterly or year-end results and will close 15 days prior to the due date for these results. This change is expected to promote transparency and align trading practices more closely with publicly available information. BioHarvest continues to leverage its patented Botanical Synthesis technology for developing innovative plant-based solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amended insider trading policy creates a more reasonable trading window.
  • Policy change may enhance transparency and shareholder trust.
  • Company continues to position itself as a leader in Botanical Synthesis technology.

Full Press Release Details

BioHarvest Sciences Amended Insider Trading Policy
Rehovot, Israel - August 13, 2025 -BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, announces today that the board of directors has adopted an amended insider trading policy (the "Amended Insider Trading Policy") to make the trading window a more reasonable period of time. The trading window under the Amended Insider Trading Policy opens after the close of trading on the second full trading day following the widespread public release of our quarterly or year-end operating results and closes fifteen (15) calendar days before the due date (which date does not include any available extension periods) of any of the Company's quarterly or year-end operating results.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations

Frequently Asked Questions

What is the amended insider trading policy of BioHarvest?

BioHarvest's amended policy establishes a trading window starting after the second full trading day post a public release of quarterly or year-end results.

When does the trading window close under the new policy?

The trading window closes fifteen calendar days before the due date of the Company’s quarterly or year-end results.

What technology does BioHarvest utilize?

BioHarvest uses its patented Botanical Synthesis technology to cultivate plant-based compounds without needing the actual plants.

What are the business areas BioHarvest focuses on?

BioHarvest operates as a contract development organization and creates proprietary nutraceutical health products.

Who can be contacted for investor relations at BioHarvest?

Dave Ryan, the VP of Investor Relations, can be contacted for inquiries regarding BioHarvest.

Last updated: Aug 13, 2025